Clinical oncology (Royal College of Radiologists (Great Britain)) | 2021

Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer.



Osimertinib is used as a first-line treatment for metastatic non-small cell lung cancer with positive epidermal growth factor receptor mutations based on the results of the FLAURA trial. However, as with any other epidermal growth factor receptor tyrosine kinase inhibitor, resistance also develops for osimertinib. Various genetic aberrations associated with the molecular heterogeneity of cancer cells contribute to osimertinib resistance. It is also important to choose an appropriate subsequent treatment for osimertinib-resistant non-small cell lung cancer. In this overview, we discuss the underlying mechanisms of osimertinib resistance and the efficacy of possible subsequent treatment measures.

Volume None
Pages None
DOI 10.1016/j.clon.2021.07.015
Language English
Journal Clinical oncology (Royal College of Radiologists (Great Britain))

Full Text